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Background: Mechanical heart valve replacement has an inherent risk of thromboembolic events (TEs).
Current guidelines recommend an international normalized ratio (INR) of at least 2.5 after mechanical mitral valve
replacement (MVR). This study aimed to evaluate the effects of a low INR (2.0–2.5) on thromboembolic and
bleeding complications in patients with mechanical MVR on warfarin therapy.
Methods: One hundred and thirty-five patients who underwent mechanical MVR were enrolled in this study. The
end points of this study were defined as TEs (valve thrombosis, transient ischemic attack, stroke) and bleeding
(all minor and major bleeding) complications. Patients were followed up for a mean of 39.6 months and the mean
INR of the patients was calculated. After data collection, patients were divided into 3 groups according to their
mean INR, as follows: group 1 (n = 34), INR <2.0; group 2 (n = 49), INR 2.0–2.5; and group 3 (n = 52), INR >2.5.
Results: A total of 22 events (10 [7.4%] thromboembolic and 12 [8.8%] bleeding events) occurred in the follow-up
period. The mean INR was an independent risk factor for the development of TEs. Mean INR and neurological
dysfunction were independent risk factors for the development of bleeding events. A statistically significant positive
correlation was found between the log mean INR and all bleeding events, and a negative correlation was found
between the log mean INR and all TEs. The total number of events was significantly lower in group 2 than in
groups 1 and 3 (P = 0.036).
Conclusions: This study showed that a target INRs of 2.0–2.5 are acceptable for preventing TEs and safe in terms of
bleeding complications in patients with mechanical MVR.
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Lifelong oral anticoagulation is recommended for all pa-
tients with mechanical heart valves irrespective of valve
type or date of introduction and is essential for the pre-
vention of thromboembolic events (TEs) [1,2]. However,
anticoagulation therapy is also associated with an in-
creased risk of bleeding complications [3]. It is import-
ant to achieve optimum anticoagulation, which prevents* Correspondence: ugurabbasbal@yahoo.com
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unless otherwise stated.both adverse thromboembolic and bleeding complica-
tions. Although current clinical guidelines—European
and American—provide evidence-based recommenda-
tions on optimum anticoagulation, there is disagreement
about the thrombogenicity of mechanical heart valves
and tailoring of anticoagulation goals [4,5]. These guide-
lines recommend higher international normalized ratios
(INRs) due to the higher rates of thromboembolic com-
plications of the prosthesis in the mitral position than in
the aortic position. A target INR range of 2.5–4.0 is the
current recommendation for patients with mechanical
mitral valve replacement (MVR) [4,5].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bal et al. Journal of Cardiothoracic Surgery 2014, 9:79 Page 2 of 6
http://www.cardiothoracicsurgery.org/content/9/1/79Many factors may contribute to poor anticoagulant con-
trol, including patient compliance, lifestyle, diet, drug in-
teractions and irregular access to controls. Therefore, it
may be difficult to achieve the target INR with vitamin-K
antagonists such as warfarin, and most patients do not
achieve the target INR. Although previous studies suggest
that a low INR is preferable and safe for mechanical heart
valves, the effect of a low INR in patients with mechanical
MVR alone has not been studied [6-12]. This study aimed
to evaluate the effect of a low INR (2.0–2.5) on thrombo-
embolic and bleeding complications in patients with
mechanical MVR on warfarin therapy.
Materials and methods
All patients who underwent solely mechanical MVR be-
tween 2004 and 2012 at the Baskent University Hospital
were considered for inclusion in the study. One hundred
and fifty-nine patients who underwent mechanical MVR
were enrolled in the study. All patients were required to
be present for outpatient assessments, twice in the first
3 months, and monthly in the remaining time after hos-
pital discharge. Patients (n = 24) who were not regular
outpatients with measured IRNs after valve surgery were
excluded. All patients were informed about the effects of
dietary habits on the coagulation parameters and used
the same source of warfarin sodium.
The same warfarin therapy was administered to all pa-
tients for anticoagulation. To evaluate anticoagulant activ-
ity, the INRs were measured every month and a mean INR
was calculated for each patient. All patients were informed
of the effects of dietary habits on the coagulation parame-
ters. The presence of bleeding and thromboembolic com-
plications was recorded. Bleeding episodes were classified
as major, minor, and minimal as described in the Thromb-
olysis in Myocardial Infarction (TIMI) trial [13]. Minimal
bleeding (gingival bleeding, ecchymosis or other episodes
of simple bleeding) was not included in the statistical ana-
lysis. Thromboembolism was defined as a transient or per-
manent neurological, limb or visceral deficit.
After data collection, patients were divided into 3 groups,
as follows: group 1, the patients with mean INR <2.0
(n = 34) that we were unable to achieve a target INR
level attributed to numerous factors including change
in diet, poor compliance with medication, and low
socio-cultural level of the patient, alcohol consumption,
seasonal variation, and drug to drug interactions; group
2, mean INR 2.0–2.5 (n = 49); and group 3, mean
INR >2.5 (n = 52). The main end points of the study
were defined as thromboembolic (valve thrombosis,
transient ischemic attack and stroke) and bleeding (all
minor and major bleeding) events.
This study has been approved by the Baskent Univer-
sity Institutional Review Board and Ethics Committee,
and supported by the Baskent University Research Fund.Statistical analysis
The statistical package SPSS (Statistical Package for the
Social Sciences, version 17.0, SSPS Inc, Chicago, Ill,
USA) was used for statistical analysis. Continuous vari-
ables were expressed as means ± standard deviation. Cat-
egorical variables were expressed as the total number
(percentage). All continuous variables were evaluated
with the Kolmogorov–Smirnov normality test to show
their distributions. Continuous variables with normal
distributions were compared using the unpaired Student
t-test and ANOVA with the Tukey’s post-hoc test. Con-
tinuous variables with abnormal distributions were com-
pared using the Mann–Whitney U test and ANOVA
with the Tukey’s post-hoc test. For categorical variables,
the chi-square test was used. Values of P < 0.05 were
considered statistically significant for all tests.
The relationship between the mean INR and thrombo-
embolic and bleeding events were examined by Pearson’s
correlation analysis.
A multiple regression analysis was performed to exam-
ine the independent predictors of bleeding and TEs. The
alternative test hypothesis was built as two-sided for
each statistical analysis. The tests were independent and
so was the experiment-wise. Type I error did not exceed
0.05 alpha levels. Univariate variables with P < 0.05 were
included in the multiple regression analysis for odds ra-
tios and 95% confidence intervals.
Results
Patients’ characteristics
Fifty (37%) of the patients were men and 85 (63%) were
women with a mean age of 51.7 ± 13.7 years. The dur-
ation of the follow-up period was 12–72 months (mean
39.6 ± 21.4 months), with a cumulative follow-up period
of 446.2 patient-years. Initial mitral valve dysfunction
was attributed to rheumatic mitral stenosis in 66.7%
(n = 90) of cases and to other causes such as functional
mitral regurgitation or chordae rupture in the remaining
33.3% (n = 45) of the cases. The reason for undergoing
surgery was similar in all groups. The baseline clinical
characteristics and laboratory parameters of the patients
are shown in Table 1.
A total of 22 thromboembolic and bleeding events
were documented in the follow-up period (Table 2).
Predictors of thromboembolic events
The incidence of TEs (10 events were documented
[7.4%]: group 1, n = 7 [20.5%]; group 2, n = 1 [2.0%];
group 3, n = 2 [3.8%]) was significantly higher in group 1
(P = 0.003) than in the other 2 groups. Four (2.9%) of
the TEs were transient ischemic attacks (TİA), (group 1,
n = 1 [2.9%]; group 2, n = 1 [2.0%]; group 3, n = 2 [3.8%])
and there was no significant difference among the 3
groups regarding TİAs (p = NS). All cases of ischemic
Table 1 The baseline clinical characteristics and laboratory parameters of the patients
Variables Group 1
n = 34
Group 2
n = 49
Group 3
n = 52
*F *p
Age, years 55.9 ± 12.9 49.9 ± 13.2 50.1 ± 14.2 2.428 0.092
Gender, male (%) 23 (67.6) 33 (67.3) 30 (57.7) - 0.516
Atrial fibrillation, n (%) 17 (50) 28 (57.1) 26 (50) - 0.727
Hypertension, n (%) 16 (47.1) 14 (28.6) 19 (36.5) - 0.227
Diabetes mellitus, n (%) 8 (23.5) 5 (10.2) 4 (7.7) - 0.079
Smoking, n (%) 5 (20) 15 (32.6) 11 (21.6) - 0.360
Neurological dysfunction, n (%) 3 (8.8) 3 (6.1) 2 (3.8) - 0.632
Follow-up time, months 33.7 ± 29.0 40.4 ± 32.9 42.8 ± 31.5 0.884 0.416
Mean LVEF, % 53.3 ± 9.8 53.2 ± 8.8 54.0 ± 9.2 0.778 0.461
Left atrium, cm 5.2 ± 0.8 5.8 ± 1.0 5.5 ± 1.0 3.727 0.027
sPAP, mmHg 40.8 ± 12.7 43.8 ± 14.7 42.2 ± 12.5 0.506 0.604
Hemoglobin, g/dL 13.6 ± 1.5 12.7 ± 1.6 12.3 ± 1.3 7.899 0.001
WBC, ×103/μL 7.8 ± 2.7 8.5 ± 2.2 7.7 ± 1.9 2.098 0.127
Platelet, ×103/μL 196.91 ± 68.1 218.98 ± 77.7 231.77 ± 78.4 2.181 0.117
Creatinine, mg/dL 1.24 ± 1.3 1.39 ± 1.5 0.9 ± 0.2 2.201 0.115
Mean INR level 1.8 ± 0.1 2.2 ± 0.1 2.8 ± 0.3 232.346 <0.001
INR: International Normalized Ratio, LVEF: Left Ventricle Ejection Fraction, sPAP: Systolic Pulmonary Arterial Pressure, WBC: White Blood Cell.
*Chi-square and ANOVA with posthoc Tukey test.
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reported in group 1 with significantly higher incidence
than that in the other 2 groups ((P = 0.002 and P = 0.049,
respectively; Table 2).
In the univariate analysis, we found that the mean INR
was significantly lower in patients with TEs than in pa-
tients without TEs (P = 0.022) and the other parameters
were similar among the groups (Table 3). Multiple step-
wise logistic regression analysis showed that the mean
INR (OR, 9.77; 95% CI, 1.26–75.52; P = 0.029) was an in-
dependent risk factor for the development of TEs in this
patient group.Table 2 Main outcomes of the patients
Variable Total
n = 135
Grou
n = 3
Thromboembolic Events, n (%) 10 (7.4) 7 (20
Valve Thrombosis, n (%) 2 (1.4) 2 (5
Stroke, n (%) 4 (2.9) 4 (11
TIA, n (%) 4 (2.9) 1 (2
Bleeding Events, n (%) 12 (8.8) 2 (5
Major, n (%) 4 (2.9) 1 (2
Minor, n (%) 8 (5.9) 1 (2
Total Events, n (%) 22 (16.2) 9 (26
TIA: Transient Ischemic Attacks.
Chi-square test.Predictors of bleeding events
A total of 12 bleeding episodes were documented in the
follow-up period (8.8%; group 1, n = 2 [5.8%]; group 2,
n = 2 [4.0%]; group 3, n = 8 [15.3%]). The bleeding events
were not significantly different between the groups (P =
0.106). There were 4 major (2.9%; group 1, n = 1 [2.9%];
group 2, n = 0 [0%]; group 3, n = 3 [5.8%]) and 8 minor
(5.9%; group 1, n = 1 [2.9%]; group 2, n = 2 [4.0%], group
3, n = 5 [9.6%]) bleeding events. Three of the major
bleeding events were documented in group 3 (5.7%; one
intracranial hemorrhage and two gastrointestinal system
bleeding events) and the other major bleeding eventp 1
4
Group 2
n = 49
Group 3
n = 52
P value
.5) 1 (2.0) 2 (3.9) 0.003
.8) 0 0 0.049
.7) 0 0 0.002
.9) 1 (2.0) 2 (3.8) 0.867
.8) 2 (4.0) 8 (15.3) 0.106
.9) 0 3 (5.8) 0.232
.9) 2 (4.0) 5 (9.6) 0.348
.4) 3 (6.1) 10 (19.2) 0.036
Table 3 Univariate analysis for presence of any thromboembolic or bleeding events
Patients with
TEs N: 10
Patients without
TEs N: 125
P value Patients with bleeding
events N: 12
Patients without bleeding
events N: 123
P value
Age, years 49.3 ± 13.8 51.7 ± 13.7 0.600 48.0 ± 9.1 51.8 ± 14.1 0.356
Gender, male (%) 4 (40.0) 45 (36.0) 1.0 4 (33.3) 45 (36.6) 1.0
Atrial fibrillation, n (%) 8 (80) 63 (50.4) 0.101 7 (58.3) 64 (52) 0,768
Hypertension, n (%) 5 (50) 44 (35.2) 0.496 4 (33.3) 45 (36.6) 1.0
Diabetes mellitus, n (%) 0 17 (13.6) 0.361 1 (8.3) 16 (13) 1.0
Smoking, n (%) 3 (37.5) 28 (24.6) 0.418 4 (33.3) 27 (24.5) 0.498
Neurological dysfunction, n (%) 2 (20) 6 (4.8) 0.109 3 (25) 5 (4.1) 0.024
Follow-up Time, months 47.1 ± 30.7 39.0 ± 30.5 0.439 53.2 ± 39.4 38.3 ± 30.4 0.117
Mean LVEF, % 55.9 ± 10.2 53.9 ± 9.1 0.514 54.0 ± 12.9 54.0 ± 8.9 0.984
Left Atrium, cm 5.6 ± 1.1 5.5 ± 1.0 0.799 5.7 ± 0.9 5.5 ± 1.0 0.642
sPAP, mmHg 44.1 ± 12.9 42.3 ± 13.5 0.692 41.9 ± 12.5 42.5 ± 13.5 0.881
Hemoglobin, g/dL 12.7 ± 1.1 13.0 ± 1.6 0.512 13.2 ± 1.4 13.0 ± 1.7 0.587
Platelet, ×103/μL 211 ± 63 218 ± 77 0.769 259 ± 57 214 ± 76 0.051
Creatinine, mg/dL 0.8 ± 0.2 1.2 ± 1.2 0.283 0.9 ± 0.2 1.2 ± 1.2 0.457
Mean INR level 2.1 ± 0.4 2.4 ± 0.5 0.022 2.4 ± 0.4 2.7 ± 0.5 0.016
INR: International Normalized Ratio, LVEF: Left Ventricle Ejection Fraction, sPAP: Systolic Pulmonary Arterial Pressure, TEs: Thromboembolic events.
Data are presented as number (percentage) and mean ± SD values.
Chi-square, unpaired Student-t test and the Mann–Whitney U test.
Table 4 Correlation between of mean INR levels and
thromboembolic or bleeding events
All patients
r p
All Thromboembolic Events −0.197 0.022
Valve Thrombosis −0.147 0.089
Stroke −0.162 0.060
TIA −0.037 0.673
All Bleeding Events 0.206 0.016
Major Bleeding 0.144 0.096
Minor Bleeding 0.146 0.092
Total Events −0.020 0.822
TIA: Transient Ischemic Attacks.
Pearson correlation analysis.
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The patient with intracranial hemorrhage in group 3
died. There were 5 minor bleeding episodes in group 3.
In the univariate analysis, we found that the mean INR
and neurological dysfunction (which was already being
due to a TE and present prior to undergoing valve sur-
gery and initiating anticoagulation) were significantly
higher in patients with bleeding events than in patients
without bleeding events (P = 0.016 and P = 0.024, re-
spectively), and the other parameters were similar in the
3 groups (Table 3). Multiple stepwise logistic regression
analysis showed that the mean INR (OR, 5.26; 95% CI,
1.41–19.6; P = 0.013) and neurological dysfunction (OR,
11.7; 95% CI, 1.99–68.5; P = 0.006) were independent
risk factors for the development of bleeding events in
this patient group.
Correlation between mean INR and thromboembolic or
bleeding events
Significant positive correlations were found between the log
mean INR and all bleeding events (r = 0.206, P = 0.016).
Negative correlations were found between the log mean
INR and all TEs (r = −0.197, P = 0.022; Table 4).
Discussion
We studied the INRs in patients undergoing mechanical
MVR, without interference with the surgeries conducted
by the treating physicians. Relatively stable drug doses
were administered. A total of 135 patients with mechan-
ical MVR were followed up, and we did not observe anysignificant differences in the incidence of TEs between
patients with INRs of 2.0–2.5 and those with INRs >2.5.
Moreover, the number of events was significantly lower
in patients with INRs of 2.0–2.5 and this patient group
was the safest group in our study.
Lifelong anticoagulation is essential for all patients
with mechanical heart valve prostheses. However, it is
difficult to achieve optimal anticoagulation with war-
farin, which requires a careful balance. Low INR may re-
sult in thromboembolic complications. In contrast, high
INR may result in bleeding complications such as intra-
cranial hemorrhages or gastrointestinal bleeding [2].
Stein at al. [14] found that the rate of morbidity from
bleeding (7% per patient year) was higher than that from
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cluded that anticoagulation should be controlled within
an ideal range to minimize bleeding complications.
Our results are consistent with those of other studies
from Asia. Mori et al. [6] studied 102 Japanese patients
with mechanical heart valve prosthesis and found a signifi-
cant increase in morbidity from bleeding with an INR >2.5.
Uetsuka et al. [7] studied 1,157 Japanese patients receiving
warfarin therapy after prosthetic valve replacement during
a mean follow-up period of 2.44 years and found that the
incidence of TEs did not increase with a lower INR of 1.5.
Therefore, they suggested that the incidence of TEs is
lower in Japan, despite a less intensive regimen.
From China, Sun et al. [8] studied 805 patients with St.
Jude Medical valves and concluded that a lower target
INR range of 2.0–2.5 is preferable for Chinese patients to
reduce severe bleeding complications in those with con-
ventionally higher INRs. Zhang et al. [9] studied 1,658 pa-
tients who underwent mechanical valve replacement and
reported that the incidence of total complications in the
group with INRs of 1.3–2.3 (aortic valve replacement:
1.3–1.8; mitral valve replacement and double valve re-
placement: 1.8–2.3) was the lowest among all anticoagu-
lant therapy regimens followed.
In a prospective study from Pakistan, Raja et al. [10]
reported that anticoagulation for mechanical heart valve
replacement can be managed with a target INR range
of 2.0–2.5, resulting in acceptable hemorrhagic and
thromboembolic events.
In western countries, Koertke et al. [11] followed 1,137
German patients in a prospective, randomized, multicen-
ter trial and demonstrated the efficacy and safety of very
low, self-managed INR doses (INR target value, 2.0;
range, 1.6–2.1) in patients with aortic valve replacement
and 2.3 (range, 2.0–2.5) in patients with mitral valve or
double valve replacement. In France, the AREVA study
reported that the incidence of thromboembolic compli-
cations was similar in patients with a target INR range
of 2.0–3.0 and those with a target INR range of 3.0–4.5;
however, there were fewer bleeding complications in the
low dose group [12].
We also found that neurological dysfunction was an
independent risk factor for bleeding events. We have at-
tributed this finding to the decreased cognitive function
and physical disability of patients with neurological dys-
function. Moreover, the inability to reach an optimal
medical control was another factor for bleeding compli-
cations in this patient group.
Socio-economic circumstances have a great role in the
management and compliance of patients with mechan-
ical MVR. Thus, the small number of patients with
optimal INR levels can be explained by the higher
rates of patients with a low socio-economic status in
this study.Study limitations
The small number of the subjects is the major limitation
of this study.
Conclusion
This study showed that a target INR range of 2.0–2.5 is
acceptable for preventing TEs and safe in terms of bleed-
ing complications in patients with mechanical MVR. In
the future, population-based INR adjustments can be pre-
ferred to continental guidelines for valve replacement pa-
tients; but however, large local studies are needed to allow
changes in current guidelines.
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